BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
BioCentury | Dec 8, 2017
Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
BioCentury | Oct 12, 2017
Preclinical News

Team describes MECP2 gene therapy approach for Rett syndrome

In a paper published in Nature , researchers at the University of Edinburgh and colleagues showed that adeno-associated virus (AAV) delivery of a shortened version of the methyl CpG binding protein 2 ( MECP2 ; RTT) gene...
BioCentury | Oct 17, 2013
Distillery Techniques

Technology: Drug platforms

...of methyl-CpG binding domain protein 3 (MBD3) for deterministic and synchronized reprogramming to pluripotency In vitro studies suggest depletion of Mbd3...
...into induced pluripotent stem (iPS) cells. In murine epiblast stem cells, small interfering RNA against Mbd3...
...transcription factors to 80% at 5 days, whereas control siRNA caused a 10% improvement. In Mbd3-depleted...
BioCentury | Jan 16, 2012
Clinical News

KAI-4169: Phase II started

KAI began an open-label Phase II trial to evaluate IV KAI-4169 given thrice weekly for 12 weeks in about 30 hemodialysis patients with chronic kidney disease-mineral and bone disorder (CKD-MBD). Ono has exclusive, Japanese rights...
BioCentury | Nov 14, 2011
Clinical News

KAI-4169: Phase II data

A double-blind, dose-escalation, U.S. Phase II trial in 78 patients with chronic kidney disease-mineral and bone disorder (CKD-MBD) showed that thrice-weekly 5 and 10 mg IV KAI-4169 given during hemodialysis each met the primary endpoint...
BioCentury | Nov 12, 2011
Clinical News

KAI-4169 meets hyperparathyroidism endpoint

KAI Pharmaceuticals Inc. (South San Francisco, Calif.) said KAI-4169 met the primary endpoint in a Phase II trial to treat secondary hyperparathyroidism. Thrice-weekly 5 and 10 mg IV doses of the product given during hemodialysis...
BioCentury | Oct 22, 2007

Circumstantially sufficient

FDA convened last week's meeting of its Cardiovascular and Renal Drugs Advisory Committee after the three companies that market phosphate binders to treat hyperphosphatemia in dialysis patients asked for guidance on extending the labels of...
BioCentury | Apr 30, 2001
Company News

National Institute of Child Health and Human Development other research news

Institute researchers published in the Proceedings of the National Academy of Sciences that MBD2 binds to the methylated regulatory regions of tumor suppressor proteins p16 and p14 in vivo and could contribute to gene silencing...
Items per page:
1 - 9 of 9